Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable, and many patients achieve long-term remission after frontline therapy. Advances in chemotherapy, radiation techniques and targeted ...

Frontline nivolumab plus AVD reduced risk of progression or death by 58% versus brentuximab vedotin plus AVD (PFS HR, 0.42) in advanced-stage classical Hodgkin lymphoma. CA209-8UT randomized 994 ...

Clinicians knew Victor Tinley had cancer four months before he was told about it, an inquest hears.

Hodgkin lymphoma and primary mediastinal B-cell lymphoma are two aggressive blood cancers that affect young people between their late teens and mid-30s, a group often referred to as Adolescents and ...

Twenty years. That's how long Robert Oman has been cancer-free, thanks to a clinical trial offered at the University of Rochester's Wilmot Cancer Institute. And he isn't alone: 70% of patients in the ...

Recent advances in cancer treatment are transforming the outlook for patients with lymphoma, offering renewed hope where options were once limited. According to Dr. Rahul Bhargava, one of India''s ...

March 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it approved Bristol Myers Squibb's combination treatment for adults and adolescents aged 12 and older with previously ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global ...

AI-guided, synthetic lethal therapy achieves complete metabolic response after just two cycles in patient who failed three prior state-of-the-art treatment regimens. Complete response in an aggressive ...

Young patients often struggle to get early diagnosis of cancer leading to delays and more advanced stages of disease.